Buy Or Sell Opportunity • 14h
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to ₩51,500. The fair value is estimated to be ₩64,976, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Meanwhile, the company became loss making. Price Target Changed • Jul 06
Price target increased by 11% to ₩99,000 Up from ₩89,000, the current price target is an average from 3 analysts. New target price is 27% above last closing price of ₩78,200. Stock is up 155% over the past year. The company is forecast to post earnings per share of ₩988 next year compared to a net loss per share of ₩5,816 last year. New Risk • Jun 08
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 27
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: ₩5,815 loss per share (down from ₩6,394 profit in FY 2024). Revenue: ₩85.5b (up 19% from FY 2024). Net loss: ₩138.3b (down 195% from profit in FY 2024). Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) also missed analyst estimates by 113%. Revenue is forecast to grow 49% p.a. on average during the next 2 years, compared to a 21% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Mar 12
L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2026 L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₩118,300, the stock trades at a trailing P/E ratio of 37.3x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 434% over the past three years. Valuation Update With 7 Day Price Move • Jan 26
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩64,900, the stock trades at a trailing P/E ratio of 20.5x. Average forward P/E is 18x in the Biotechs industry in South Korea. Total returns to shareholders of 201% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩30,982 per share. Aankondiging • Dec 24
L&C BIO Co.,LTD has filed a Follow-on Equity Offering in the amount of KRW 14.999981 billion. L&C BIO Co.,LTD has filed a Follow-on Equity Offering in the amount of KRW 14.999981 billion.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 223,214
Price\Range: KRW 67200 Upcoming Dividend • Dec 22
Upcoming dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 15 April 2026. Payout ratio is a comfortable 1.5% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (0.6%). Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩61,500, the stock trades at a trailing P/E ratio of 19.2x. Average forward P/E is 16x in the Biotechs industry in South Korea. Total returns to shareholders of 152% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩31,355 per share. Declared Dividend • Nov 08
Dividend of ₩50.00 announced Dividend of ₩50.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 15th April 2026 Dividend yield will be 0.1%, which is lower than the industry average of 0.5%. Aankondiging • Nov 07
L&C BIO Co.,LTD announces Annual dividend, payable on April 15, 2026 L&C BIO Co.,LTD announced Annual dividend of KRW 50.0000 per share payable on April 15, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Valuation Update With 7 Day Price Move • Oct 01
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₩50,800, the stock trades at a trailing P/E ratio of 9.9x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 123% over the past three years. New Risk • Sep 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (47% accrual ratio). Valuation Update With 7 Day Price Move • Sep 05
Investor sentiment improves as stock rises 36% After last week's 36% share price gain to ₩42,150, the stock trades at a trailing P/E ratio of 8.2x. Average forward P/E is 22x in the Biotechs industry in South Korea. Total returns to shareholders of 74% over the past three years. Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩34,500, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 16% over the past three years. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩32,000, the stock trades at a trailing P/E ratio of 5.6x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 3.2% over the past three years. Aankondiging • Jun 23
L&C BIO Co.,LTD (KOSDAQ:A290650) announces an Equity Buyback for 342,465 shares, for KRW 10,000 million. L&C BIO Co., Ltd (KOSE:A290650) announces a share repurchase program. Under the program, the company will repurchase up to 342,465 shares for KRW 10,000 million. The purpose of the program is to stabilize stock price and enhance shareholder value The share repurchase program is valid until September 23, 2025. As of June 22, 2025, the company had no shares in treasury within scope available for dividend and had no shares in treasury through other repurchase. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩30,400, the stock trades at a trailing P/E ratio of 5.3x. Average trailing P/E is 25x in the Biotechs industry in South Korea. Total loss to shareholders of 8.4% over the past three years. New Risk • May 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (55% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.4% average weekly change). Valuation Update With 7 Day Price Move • May 21
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₩29,150, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 28x in the Biotechs industry in South Korea. Total loss to shareholders of 26% over the past three years. Aankondiging • Mar 13
L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2025 L&C BIO Co.,LTD, Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 8, dunchon-daero 457beon-gil, jungwon-gu, gyeonggi-do, seongnam South Korea Aankondiging • Jan 22
L&C Bio Secures NMPA Approval for 'Megaderm Plus' in China L&C Bio has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval from China's National Medical Products Administration (NMPA) for its acellular dermal matrix, "MegaDerm Plus." This approval positions the company to potentially dominate China's regenerative medicine market for human tissue, with full-scale sales expected to commence in the first half of 2025. China has recently faced a shortage of human tissue products due to incidents involving illegal donor acquisitions, leading to unprecedented shutdowns of major local companies. In this challenging environment, "MegaDerm Plus," now officially approved by the Chinese government, has emerged as a pivotal product that could effectively address this shortage. Interest in "MegaDerm Plus" has already surged among China's leading medical device companies, hospitals, and medical professionals, raising strong prospects for consecutive sales agreements. This positions L&C Bio not only for market entry but also for establishing a decisive foothold in China's regenerative medicine market for human tissue. Upcoming Dividend • Dec 20
Upcoming dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 14 April 2025. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.9%). In line with average of industry peers (0.5%). Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₩16,700, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 23x in the Biotechs industry in South Korea. Total loss to shareholders of 52% over the past three years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩100.00 per share at 0.2% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 15 April 2024. Payout ratio is a comfortable 2.1% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (0.7%). Reported Earnings • Nov 19
Third quarter 2023 earnings released: EPS: ₩2,176 (vs ₩14.00 in 3Q 2022) Third quarter 2023 results: EPS: ₩2,176 (up from ₩14.00 in 3Q 2022). Revenue: ₩20.6b (up 61% from 3Q 2022). Net income: ₩49.8b (up ₩49.5b from 3Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Biotechs industry in South Korea. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩26,300, the stock trades at a trailing P/E ratio of 53.8x. Average trailing P/E is 24x in the Biotechs industry in South Korea. Total returns to shareholders of 72% over the past three years. Upcoming Dividend • Dec 21
Upcoming dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 13 April 2023. Payout ratio is a comfortable 10% but the company is not cash flow positive. Trailing yield: 0.2%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (0.7%). Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment improved over the past week After last week's 15% share price gain to ₩25,100, the stock trades at a trailing P/E ratio of 45.4x. Average trailing P/E is 19x in the Biotechs industry in South Korea. Total returns to shareholders of 211% over the past three years. Valuation Update With 7 Day Price Move • Oct 11
Investor sentiment deteriorated over the past week After last week's 25% share price decline to ₩17,500, the stock trades at a trailing P/E ratio of 31.7x. Average trailing P/E is 20x in the Biotechs industry in South Korea. Total returns to shareholders of 117% over the past three years. Aankondiging • Jul 01
L&C Bio Co., Ltd announced that it has received KRW 60 billion in funding On June 29, 2022, L&C Bio Co., Ltd closed the transaction. Valuation Update With 7 Day Price Move • May 23
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₩36,150, the stock trades at a forward P/E ratio of 79x. Average forward P/E is 25x in the Biotechs industry in South Korea. Total returns to shareholders of 373% over the past three years. Upcoming Dividend • Dec 22
Upcoming dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 10% and the cash payout ratio is 80%. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (0.8%). Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment improved over the past week After last week's 17% share price gain to ₩36,950, the stock trades at a forward P/E ratio of 65x. Average forward P/E is 26x in the Biotechs industry in South Korea. Total returns to shareholders of 490% over the past three years. Reported Earnings • Nov 15
Third quarter 2021 earnings released: EPS ₩77.00 (vs ₩86.00 in 3Q 2020) The company reported a mediocre third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: ₩11.9b (up 44% from 3Q 2020). Net income: ₩1.76b (down 6.6% from 3Q 2020). Profit margin: 15% (down from 23% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 76% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Feb 22
New 90-day low: ₩30,400 The company is down 17% from its price of ₩36,600 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period. Is New 90 Day High Low • Jan 18
New 90-day low: ₩30,650 The company is down 30% from its price of ₩43,950 on 20 October 2020. The South Korean market is up 30% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period. Is New 90 Day High Low • Dec 28
New 90-day low: ₩33,050 The company is down 28% from its price of ₩45,667 on 29 September 2020. The South Korean market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩5,058 per share. Upcoming Dividend • Dec 22
Upcoming Dividend of ₩50.00 Per Share Will be paid on the 10th of April to those who are registered shareholders by the 29th of December. The trailing yield of 0.09% is below the top quartile of South Korean dividend payers (2.6%), and is lower than industry peers (0.3%). Is New 90 Day High Low • Dec 08
New 90-day low: ₩34,100 The company is down 22% from its price of ₩43,500 on 09 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,530 per share. Reported Earnings • Nov 17
Third quarter 2020 earnings released: EPS ₩257 The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2020 results: Revenue: ₩8.32b (up 21% from 3Q 2019). Net income: ₩1.88b (up 14% from 3Q 2019). Profit margin: 23% (down from 24% in 3Q 2019). The decrease in margin was driven by higher expenses. Is New 90 Day High Low • Nov 06
New 90-day low: ₩38,950 The company is down 15% from its price of ₩45,733 on 07 August 2020. The South Korean market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩4,305 per share. Is New 90 Day High Low • Oct 06
New 90-day high: ₩155,600 The company is up 44% from its price of ₩108,100 on 08 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩13,045 per share.